Research & Development

Data from Pivotal Trials of Etripamil in PSVT

Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study

Journal of the American Heart Association

Self-administered Intranasal Etripamil Using a Symptom-prompted, Repeat-dose Regimen for Atrioventricular-nodal-dependent Supraventricular Tachycardia (RAPID): A Multicentre, Randomised Trial

The Lancet

Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients with Supraventricular Tachycardia

ISPOR

Self-administered Etripamilfor Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis fromthe RAPID Study

American Heart Association

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)

American Heart Association

Rationale For and Design ofa Multicenter, Placebo-controlled, Phase 3 Study to Assess Efficacy and Safety of Intranasal Etripamilforthe Conversion of Paroxysmal Supraventricular Tachycardia

American Heart Journal

HRS 22: Long-Term Outcomes of the NODE-302 Study | Dr James Ip

Heart Rhythm Society

Analysis of Clinical Outcomes in the NODE-301 Trial

American College of Cardiology

Additional Clinical Data of Etripamil in PSVT

Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings

EHRA

Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study

Heart Rhythm Society

Etripamil Nasal Spray Reduces Heart Rate in Patients with Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm

American Heart Association

Etripamil Nasal Spray for Acute Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

Heart Rhythm Society

Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. Journal of the American College of Cardiology. 2018.

Journal of the American College of Cardiology

Clinical Data of Etripamil in Atrial-Fibrillation with Rapid Ventricular Response (AF-RVR)

A Multicenter, Phase 2, Randomized, Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Symptomatic Atrial Fibrillation (ReVeRA-201)

Circulation: Arrhythmia and Electrophysiology

Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients with Atrial Fibrillation: Phase 2 ReVeRa-201

American Heart Association

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation

Heart Rhythm Society

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster

Heart Rhythm Society

PSVT Disease Burden

Prevalence and Incidence of Patients with Paroxysmal Supraventricular Tachycardia inthe United States.

Journal of Cardiovascular Electrophysiology

Trends in Healthcare Resource Use and Expenditures in Patients with Newly Diagnosed Paroxysmal Supraventricular Tachycardia in the United States. 2021.

American Heart Journal

Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. Journal of the American Heart Association. 2020.

Journal of the American Heart Association

Healthcare Resource Use and Expenditures in Patients Newly Diagnosed with Paroxysmal Supraventricular Tachycardia. American Journal of Cardiology. 2020.

American Journal of Cardiology